Early Prediction by 18F-FDG PET/CT for Progression-Free Survival and Overall Survival in Patients With Metastatic Colorectal Cancer Receiving Third-Line Cetuximab-Based Therapy
| Autor: | Feng-Yuan Liu, Tsai-Sheng Yang, Jeng-Yi Wang, Tzu-Chen Yen |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Colorectal cancer Cetuximab Antineoplastic Agents Antibodies Monoclonal Humanized Multimodal Imaging Disease-Free Survival Fluorodeoxyglucose F18 Internal medicine medicine Overall survival Humans Radiology Nuclear Medicine and imaging In patient Progression-free survival Neoplasm Metastasis neoplasms Aged business.industry General Medicine Middle Aged medicine.disease Regimen Treatment Outcome Response Evaluation Criteria in Solid Tumors Tumor progression Positron-Emission Tomography Female Radiopharmaceuticals Colorectal Neoplasms Tomography X-Ray Computed business Nuclear medicine medicine.drug |
| Zdroj: | Clinical Nuclear Medicine. 40:200-205 |
| ISSN: | 0363-9762 |
| DOI: | 10.1097/rlu.0000000000000693 |
| Popis: | OBJECTIVE In metastatic colorectal cancer (mCRC) with wild-type K-ras, cetuximab-based regimen is an option for third-line therapy. The objective of this study was to assess if early response evaluation by 18F-FDG PET/CT can predict progression-free survival (PFS) and overall survival (OS) in these patients. PATIENTS AND METHODS Patients with mCRC going to receive third-line cetuximab-based therapy were enrolled. 18F-FDG PET/CT studies were arranged at baseline and at the ends of the first and fourth weeks of therapy. Treatment response was evaluated with 2 methods: method 1 based on PET response criteria in solid tumors 1.0 and method 2 based on the assumption that an increase in peak tumor metabolism implies nonresponse. Progression-free survival was counted to tumor progression based on the Response Evaluation Criteria in Solid Tumors 1.1 or death. The predictive powers for PFS and OS were analyzed using the Kaplan-Meier method and the log-rank test. RESULTS Twenty-seven patients were eligible with a median PFS of 5.8 months and a median OS of 9.1 months. Method 2 predicts PFS (P = 0.001) and OS (P < 0.001) at the end of the first week, whereas method 1 does not. Both methods predict PFS and OS at the end of the fourth week. CONCLUSIONS Early response evaluation by 18F-FDG PET/CT predicts PFS and OS in patients with mCRC receiving third-line cetuximab-based therapy. Early therapeutic change may be possible for nonresponsive patients after 1 week of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|